Fragile X

Translation in action

Mark F. Bear, Gul Dolen, Emily Osterweil, Naveen Nagarajan

Research output: Contribution to journalArticle

Abstract

Fragile X is a synapsopathy - a disorder of synaptic function and plasticity. Recent studies using mouse models of the disease suggest that the critical defect is altered regulation of synaptic protein synthesis. Various strategies to restore balanced synaptic protein synthesis have been remarkably successful in correcting widely varied mutant phenotypes in mice. Insights gained by the study of synaptic plasticity in animal models of fragile X have suggested novel therapeutic approaches, not only for human fragile X but also for autism and mental retardation of unknown etiology.

Original languageEnglish (US)
Pages (from-to)84-87
Number of pages4
JournalNeuropsychopharmacology
Volume33
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Neuronal Plasticity
Autistic Disorder
Intellectual Disability
Proteins
Animal Models
Phenotype
Therapeutics

Keywords

  • Autism
  • Cerebral protein synthesis
  • Developmental disorder
  • Fragile x
  • Metabotropic glutamate receptor
  • Synaptic plasticity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bear, M. F., Dolen, G., Osterweil, E., & Nagarajan, N. (2008). Fragile X: Translation in action. Neuropsychopharmacology, 33(1), 84-87. https://doi.org/10.1038/sj.npp.1301610

Fragile X : Translation in action. / Bear, Mark F.; Dolen, Gul; Osterweil, Emily; Nagarajan, Naveen.

In: Neuropsychopharmacology, Vol. 33, No. 1, 01.2008, p. 84-87.

Research output: Contribution to journalArticle

Bear, MF, Dolen, G, Osterweil, E & Nagarajan, N 2008, 'Fragile X: Translation in action', Neuropsychopharmacology, vol. 33, no. 1, pp. 84-87. https://doi.org/10.1038/sj.npp.1301610
Bear, Mark F. ; Dolen, Gul ; Osterweil, Emily ; Nagarajan, Naveen. / Fragile X : Translation in action. In: Neuropsychopharmacology. 2008 ; Vol. 33, No. 1. pp. 84-87.
@article{6f68b341d5764a1f8a9d77019e4bef14,
title = "Fragile X: Translation in action",
abstract = "Fragile X is a synapsopathy - a disorder of synaptic function and plasticity. Recent studies using mouse models of the disease suggest that the critical defect is altered regulation of synaptic protein synthesis. Various strategies to restore balanced synaptic protein synthesis have been remarkably successful in correcting widely varied mutant phenotypes in mice. Insights gained by the study of synaptic plasticity in animal models of fragile X have suggested novel therapeutic approaches, not only for human fragile X but also for autism and mental retardation of unknown etiology.",
keywords = "Autism, Cerebral protein synthesis, Developmental disorder, Fragile x, Metabotropic glutamate receptor, Synaptic plasticity",
author = "Bear, {Mark F.} and Gul Dolen and Emily Osterweil and Naveen Nagarajan",
year = "2008",
month = "1",
doi = "10.1038/sj.npp.1301610",
language = "English (US)",
volume = "33",
pages = "84--87",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Fragile X

T2 - Translation in action

AU - Bear, Mark F.

AU - Dolen, Gul

AU - Osterweil, Emily

AU - Nagarajan, Naveen

PY - 2008/1

Y1 - 2008/1

N2 - Fragile X is a synapsopathy - a disorder of synaptic function and plasticity. Recent studies using mouse models of the disease suggest that the critical defect is altered regulation of synaptic protein synthesis. Various strategies to restore balanced synaptic protein synthesis have been remarkably successful in correcting widely varied mutant phenotypes in mice. Insights gained by the study of synaptic plasticity in animal models of fragile X have suggested novel therapeutic approaches, not only for human fragile X but also for autism and mental retardation of unknown etiology.

AB - Fragile X is a synapsopathy - a disorder of synaptic function and plasticity. Recent studies using mouse models of the disease suggest that the critical defect is altered regulation of synaptic protein synthesis. Various strategies to restore balanced synaptic protein synthesis have been remarkably successful in correcting widely varied mutant phenotypes in mice. Insights gained by the study of synaptic plasticity in animal models of fragile X have suggested novel therapeutic approaches, not only for human fragile X but also for autism and mental retardation of unknown etiology.

KW - Autism

KW - Cerebral protein synthesis

KW - Developmental disorder

KW - Fragile x

KW - Metabotropic glutamate receptor

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=36549017140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549017140&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301610

DO - 10.1038/sj.npp.1301610

M3 - Article

VL - 33

SP - 84

EP - 87

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -